Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Portfolio Pulse from
Traws Pharma has announced progress in developing tivoxavir marboxil, an investigational therapy for H5N1 bird flu. Phase 1 dosing is complete, showing potent inhibition of drug-resistant and bird flu viruses. A Phase 2 study is expected to begin in the first half of 2025.
December 23, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Traws Pharma has completed Phase 1 dosing of tivoxavir marboxil, showing potent inhibition of H5N1 bird flu. Phase 2 study is planned for H1 2025, indicating progress in their influenza program.
The completion of Phase 1 with positive results and the announcement of a Phase 2 study indicates significant progress in Traws Pharma's development of tivoxavir marboxil. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100